罗索那班
化合物
罗索那班（INN：Rosonabant，开发代号：E-6776）或译作罗索纳班，是一种用作CB1受体拮抗剂/反向激动剂的药物，埃斯特夫正在研究将其作为治疗肥胖症的食欲抑制剂。[1][2]在相关的CB1拮抗剂利莫那班于2008年11月停用后不久，临床用药的开发明显停止，原因是有报道称其及其它类似药剂会引起严重的精神不良反应，例如焦虑、抑郁和自杀意念。[3][4][5]
 | |
| 临床资料 | |
|---|---|
| ATC码 |
|
| 识别信息 | |
| |
| CAS号 | 861151-12-4 |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| 化学信息 | |
| 化学式 | C21H21Cl3N4O |
| 摩尔质量 | 451.78 g·mol−1 |
| 3D模型（JSmol） | |
| |
| |
参见
编辑参考资料
编辑- ^ Janero DR, Makriyannis A. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opinion on Emerging Drugs. March 2009, 14 (1): 43–65. PMID 19249987. S2CID 74250986. doi:10.1517/14728210902736568.
- ^ Tim C. Kirkham; S. J. Cooper. Appetite and Body Weight: Integrative Systems and the Development of Anti-Obesity Drugs. Academic Press. 2007: 325 [12 May 2012]. ISBN 978-0-12-370633-1.
- ^ Heal DJ, Gosden J, Smith SL. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. British Journal of Clinical Pharmacology. December 2009, 68 (6): 861–74. PMC 2810797
. PMID 20002080. doi:10.1111/j.1365-2125.2009.03549.x.
- ^ Lee HK, Choi EB, Pak CS. The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents. Current Topics in Medicinal Chemistry. 2009, 9 (6): 482–503. PMID 19689362. doi:10.2174/156802609788897844. （原始内容存档于2013-05-22）.
- ^ Moreira, Fabrício A.; Crippa, José Alexandre S. The psychiatric side-effects of rimonabant. Revista Brasileira de Psiquiatria. June 2009, 31 (2): 145–153. ISSN 1516-4446. PMID 19578688. doi:10.1590/S1516-44462009000200012 .
